Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Association of Basal hyperglucagonemia with impaired glucagon counterregulation in type 1 diabetes.

Farhy LS, Chan A, Breton MD, Anderson SM, Kovatchev BP, McCall AL.

Front Physiol. 2012 Feb 28;3:40. doi: 10.3389/fphys.2012.00040. eCollection 2012.

3.

Pancreatic network control of glucagon secretion and counterregulation.

Farhy LS, McCall AL.

Methods Enzymol. 2009;467:547-81. doi: 10.1016/S0076-6879(09)67021-X.

5.

Amplification of pulsatile glucagon counterregulation by switch-off of alpha-cell-suppressing signals in streptozotocin-treated rats.

Farhy LS, Du Z, Zeng Q, Veldhuis PP, Johnson ML, Brayman KL, McCall AL.

Am J Physiol Endocrinol Metab. 2008 Sep;295(3):E575-85. doi: 10.1152/ajpendo.90372.2008. Epub 2008 Jun 24.

6.

Optimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiency.

Farhy LS, McCall AL.

Diabetes Obes Metab. 2011 Oct;13 Suppl 1:133-43. doi: 10.1111/j.1463-1326.2011.01455.x. Review.

7.

Inhibition of glucagon secretion.

Young A.

Adv Pharmacol. 2005;52:151-71. Review.

PMID:
16492545
10.

Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion.

Bolli G, de Feo P, Compagnucci P, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P, Gerich JE.

Diabetes. 1983 Feb;32(2):134-41.

PMID:
6337896
11.

The role of intramyocellular lipids during hypoglycemia in patients with intensively treated type 1 diabetes.

Bernroider E, Brehm A, Krssak M, Anderwald C, Trajanoski Z, Cline G, Shulman GI, Roden M.

J Clin Endocrinol Metab. 2005 Oct;90(10):5559-65. Epub 2005 Jul 5.

PMID:
15998784
12.

Defective activation of skeletal muscle and adipose tissue lipolysis in type 1 diabetes mellitus during hypoglycemia.

Enoksson S, Caprio SK, Rife F, Shulman GI, Tamborlane WV, Sherwin RS.

J Clin Endocrinol Metab. 2003 Apr;88(4):1503-11.

PMID:
12679430
13.

Role of hepatic glycogen breakdown in defective counterregulation of hypoglycemia in intensively treated type 1 diabetes.

Kishore P, Gabriely I, Cui MH, Di Vito J, Gajavelli S, Hwang JH, Shamoon H.

Diabetes. 2006 Mar;55(3):659-66.

15.

Glucose counterregulation, hypoglycemia, and intensive insulin therapy in diabetes mellitus.

Cryer PE, Gerich JE.

N Engl J Med. 1985 Jul 25;313(4):232-41. Review.

PMID:
2861565
16.

Effects of insulin treatment without and with recurrent hypoglycemia on hypoglycemic counterregulation and adrenal catecholamine-synthesizing enzymes in diabetic rats.

Inouye KE, Yue JT, Chan O, Kim T, Akirav EM, Park E, Riddell MC, Burdett E, Matthews SG, Vranic M.

Endocrinology. 2006 Apr;147(4):1860-70. Epub 2006 Jan 5.

PMID:
16396986
17.

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, Schmiegel WH.

J Clin Endocrinol Metab. 2002 Mar;87(3):1239-46.

PMID:
11889194
19.

Leptin acts in the brain to influence hypoglycemic counterregulation: disparate effects of acute and recurrent hypoglycemia on glucagon release.

Reno CM, Ding Y, Sherwin R.

Am J Physiol Endocrinol Metab. 2015 Dec 15;309(12):E960-7. doi: 10.1152/ajpendo.00361.2015. Epub 2015 Oct 27.

20.

Lilly lecture 1988. Glucose counterregulation and its impact on diabetes mellitus.

Gerich JE.

Diabetes. 1988 Dec;37(12):1608-17. Review.

PMID:
3056759

Supplemental Content

Support Center